Skip to main content
GDRX
NASDAQ Technology

GoodRx Reports Q1 Revenue Decline and 89% Net Income Drop, but Raises Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$2.54
Mkt Cap
$880.416M
52W Low
$1.77
52W High
$5.81
52W Position info
44% above low
Off High info
56% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GDRX sits 44% above its 52-week low of $1.77.

Summary

GoodRx reported a 4% revenue decrease and an 89.4% net income drop in Q1 2026, driven by declines in prescription transactions, but saw strong growth in Pharma Direct and subscriptions, leading management to raise its full-year 2026 guidance.


Key Events · Earnings and Guidance · GDRX

  • Q1 2026 Financial Performance

    Total revenue decreased 4% year-over-year to $194.0 million, and net income fell 89.4% to $1.2 million, primarily due to a significant downturn in the core prescription transactions business.

  • Segment Performance Divergence

    Prescription transactions revenue declined 24% to $113.7 million, while Pharma Direct revenue surged 82% to $52.2 million and subscription revenue increased 16% to $24.4 million.

  • Full-Year 2026 Guidance Raised

    Management raised its full-year revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million, indicating improved outlook despite Q1 results.

  • Share Repurchase Activity

    The company repurchased 5.5 million shares of Class A common stock for an aggregate of $12.6 million during the first quarter, with $60.2 million remaining under its authorization.


Analysis · GDRX · Technology

GoodRx Holdings reported a challenging first quarter for 2026, with total revenue decreasing 4% year-over-year to $194.0 million and net income plummeting 89.4% to $1.2 million. The core prescription transactions revenue saw a significant 24% decline, attributed to broader changes in the retail pharmacy landscape and lower unit economics. However, the company demonstrated strong growth in its Pharma Direct segment, which surged 82% to $52.2 million, and subscription revenue, which increased 16% to $24.4 million. Despite the Q1 declines, management raised its full-year 2026 revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million, signaling improved confidence in future performance relative to prior internal forecasts. The company also repurchased 5.5 million shares for $12.6 million during the quarter, reflecting its commitment to capital allocation priorities.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GDRX was trading at $2.54 on NASDAQ in the Technology sector, with a market capitalization of approximately $880.4M. The 52-week trading range was $1.77 to $5.81. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GDRX - Latest Insights

GDRX
Nov 10, 2026, 6:39 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.58
Real-time Price: $3.36 info
Change: -$0.220 (-6%) info
Market Cap: $1.146B info
GDRX
Nov 02, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.55
Real-time Price: $3.36 info
Change: -$0.190 (-5%) info
Market Cap: $1.146B info
GDRX
Aug 26, 2026, 9:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $3.36 info
Change: -$0.120 (-3%) info
Market Cap: $1.146B info
GDRX
Aug 26, 2026, 9:20 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $3.36 info
Change: -$0.120 (-3%) info
Market Cap: $1.146B info
GDRX
Aug 05, 2026, 5:09 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.43
Real-time Price: $3.36 info
Change: -$0.070 (-2%) info
Market Cap: $1.146B info